Antiviral Drugs - Jordan

Jordan

The projected revenue in the Antiviral Drugs market for Jordan is expected to reach US$12.86m by 2024.
It is anticipated that the revenue will show an annual growth rate (CAGR 2024-2029) of 1.55%, leading to a market volume of US$13.89m by 2029.
In comparison to other countries, United States is expected to generate the highest revenue, amounting to US$30,640.00m in 2024.
Jordan is emerging as a leading player in the antiviral drugs market, with its strong pharmaceutical industry and focus on research and development.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Jordan has seen a steady growth in recent years.

Customer preferences: Jordan has a high prevalence of infectious diseases, including hepatitis C, influenza, and HIV/AIDS, which has led to an increased demand for antiviral drugs. Moreover, the COVID-19 pandemic has also contributed to the growth of the antiviral drugs market in Jordan, with a surge in demand for drugs such as Remdesivir and Hydroxychloroquine.

Trends in the market: The antiviral drugs market in Jordan is dominated by generic drugs due to the high cost of branded drugs. The government's efforts to increase access to healthcare services have also contributed to the growth of the market. The rise in the number of cases of infectious diseases in Jordan has led to an increase in the production of antiviral drugs by local pharmaceutical companies.

Local special circumstances: Jordan's strategic location makes it a hub for pharmaceutical trade in the Middle East. The country has a well-established pharmaceutical industry, with many local companies manufacturing and exporting generic drugs. The government has also implemented policies to encourage investment in the pharmaceutical sector, which has led to an increase in the number of local companies producing antiviral drugs.

Underlying macroeconomic factors: Jordan's economy heavily relies on foreign aid and remittances, which has led to a high level of government debt. The government's efforts to reduce healthcare costs have led to a decrease in the prices of drugs, including antiviral drugs. The COVID-19 pandemic has also had a significant impact on Jordan's economy, with a decline in tourism and a decrease in remittances. However, the government's efforts to increase access to healthcare services have led to an increase in the demand for antiviral drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.